Abstract
Ubiquitous conventional plastics, generally manufactured from finite, nonsustainable fossil fuels are non-biodegradable wonder entities but their ill effect on Mother Nature has subsequently raised major environmental concerns like their safe disposal, solid waste management and several potential hazards. Such concerns have fuelled initiatives for research globally towards development of sustainable and eco-friendly bioplastics. The new generation of plastics called ‘bioplastics’ are polymers of long chain of repeating monomer units that are classified as photodegradable, semi-biodegradable, chemically synthesized and polyhydroxyalkanoates (PHAs). The commonly emerged novel bioplastics are polyesters of hydroxyalkanoates (HAs) called PHAs, which are lipoidic storage materials found in the cytosol of vast and diverse forms of bacteria. Among 150 different PHAs known so far, poly- 3-hydroxybutyrate is the most common and comprehensively characterized PHA. Interestingly, PHAs are only completely biodegradable plastics with material properties comparable to conventional plastics that can be achieved by regulating the co-monomers incorporation into PHAs backbone. PHA bioplastics are exploited in the form of user-friendly goods viz. films, absorbable sutures, bone plates, drug carriers, etc. Besides advantages, such useful entity(s) has major shortcomings as well like high production cost compared to conventional plastics. Precisely, in PHAs production, about fifty percent of the overall price is due to the carbon substrates. Consequently, exploring novel cost-effective substrates is a major compulsion for successful commercialization of this bioplastic, which is anticipated to reduce the cost of production as a result of advancing and intensifying research work. This review presents an insight and patent developments in the field of PHAs bioplastics.
Keywords: Bioplastics, completely biodegradable plastics, low-cost carbon sources, patents, photodegradable plastics, polyhydroxyalkanoates, PHAs, semi-biodegradable plastics.
Graphical Abstract
Recent Patents on Biotechnology
Title:Commercialization of Bacterial Cell Factories for the Sustainable Production of Polyhydroxyalkanoate Thermoplastics: Progress and Prospects
Volume: 9 Issue: 1
Author(s): Abhishek Kumar, Janmejai K. Srivastava, Nirupama Mallick and Akhilesh K. Singh
Affiliation:
Keywords: Bioplastics, completely biodegradable plastics, low-cost carbon sources, patents, photodegradable plastics, polyhydroxyalkanoates, PHAs, semi-biodegradable plastics.
Abstract: Ubiquitous conventional plastics, generally manufactured from finite, nonsustainable fossil fuels are non-biodegradable wonder entities but their ill effect on Mother Nature has subsequently raised major environmental concerns like their safe disposal, solid waste management and several potential hazards. Such concerns have fuelled initiatives for research globally towards development of sustainable and eco-friendly bioplastics. The new generation of plastics called ‘bioplastics’ are polymers of long chain of repeating monomer units that are classified as photodegradable, semi-biodegradable, chemically synthesized and polyhydroxyalkanoates (PHAs). The commonly emerged novel bioplastics are polyesters of hydroxyalkanoates (HAs) called PHAs, which are lipoidic storage materials found in the cytosol of vast and diverse forms of bacteria. Among 150 different PHAs known so far, poly- 3-hydroxybutyrate is the most common and comprehensively characterized PHA. Interestingly, PHAs are only completely biodegradable plastics with material properties comparable to conventional plastics that can be achieved by regulating the co-monomers incorporation into PHAs backbone. PHA bioplastics are exploited in the form of user-friendly goods viz. films, absorbable sutures, bone plates, drug carriers, etc. Besides advantages, such useful entity(s) has major shortcomings as well like high production cost compared to conventional plastics. Precisely, in PHAs production, about fifty percent of the overall price is due to the carbon substrates. Consequently, exploring novel cost-effective substrates is a major compulsion for successful commercialization of this bioplastic, which is anticipated to reduce the cost of production as a result of advancing and intensifying research work. This review presents an insight and patent developments in the field of PHAs bioplastics.
Export Options
About this article
Cite this article as:
Kumar Abhishek, K. Srivastava Janmejai, Mallick Nirupama and K. Singh Akhilesh, Commercialization of Bacterial Cell Factories for the Sustainable Production of Polyhydroxyalkanoate Thermoplastics: Progress and Prospects, Recent Patents on Biotechnology 2015; 9 (1) . https://dx.doi.org/10.2174/2211550104666150615211414
DOI https://dx.doi.org/10.2174/2211550104666150615211414 |
Print ISSN 1872-2083 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4012 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
HSV-1-Derived Recombinant and Amplicon Vectors for Gene Transfer and Gene Therapy
Current Gene Therapy Indoleamine 2,3-Dioxygenase, an Emerging Target for Anti-Cancer Therapy
Current Cancer Drug Targets The Role of Insulin Receptor Isoforms and Hybrid Insulin/IGF-I Receptors in Human Cancer
Current Pharmaceutical Design In Situ Gels Based Drug Delivery Systems
Current Drug Therapy Cancer Stem Cells with Overexpression of Neuronal Markers Enhance Chemoresistance and Invasion in Retinoblastoma
Current Cancer Drug Targets Stearoyl-CoA Desaturase-1 and the Metabolic Syndrome
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Redox mechanisms in pathological angiogenesis in the retina: roles for NADPH oxidase
Current Pharmaceutical Design Integration and Querying of Heterogeneous Omics Semantic Annotations for Biomedical and Biomolecular Knowledge Discovery
Current Bioinformatics Hypoxia-Inducible Factor-1 as Regulator of Angiogenesis in Rheumatoid Arthritis - Therapeutic Implications
Current Medicinal Chemistry Genomics for Weed Science
Current Genomics Current Prospects of Nutraceuticals: A Review
Current Pharmaceutical Biotechnology Recent Advances in Drug Delivery: Potential and Limitations of Carbon Nanotubes
Recent Patents on Drug Delivery & Formulation Clinical, Prognostic and Therapeutic Significance of Heat Shock Proteins in Cancer
Current Drug Targets Transcriptional Regulation of mPGES1 in Cancer: An Alternative Approach to Drug Discovery?
Current Drug Targets Glycosyltransferase and Glypiation Inhibitors
Current Organic Chemistry Recent Developments in the Reactivity of the Biginelli Compounds
Current Organic Synthesis Strategic Aspects of NPY-Based Monoclonal Antibodies for Diagnosis and Treatment of Breast Cancer
Current Protein & Peptide Science The General Practitioners Role in Promoting Physical Activity to Older Adults: A Review Based on Program Theory
Current Aging Science Experimental Drugs for Neuropathic Pain
Current Neuropharmacology Estimation of Human Carbonic Anhydrase II Inhibition Using Topological Indices and their Combination with Quantum-Theoretical Descriptors
Medicinal Chemistry